Iambic Therapeutics, Inc. (NASDAQ:IAM – Get Free Report) rose 5.6% on Tuesday. The company traded as high as $13.00 and last traded at $12.51. 26,667 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 690,737 shares. The stock had previously closed at $11.85.
Analyst Ratings Changes
IAM has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Iambic Therapeutics to a “hold” rating in a research note on Saturday, November 7th. JPMorgan Chase & Co. began coverage on shares of Iambic Therapeutics in a report on Monday, November 9th. They set an “overweight” rating and a $22.00 price objective for the company. Jefferies Financial Group assumed coverage on shares of Iambic Therapeutics in a research report on Tuesday, November 10th. They issued a “buy” rating and a $35.00 price objective on the stock. Bank of America started coverage on shares of Iambic Therapeutics in a research note on Monday, November 9th. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Citigroup assumed coverage on shares of Iambic Therapeutics in a research note on Monday, November 9th. They set a “buy” rating and a $22.00 price target for the company. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Iambic Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $27.25.
Iambic Therapeutics Price Performance
Insider Buying and Selling
In other Iambic Therapeutics news, Director Evan Lockwood Rachlin purchased 718,750 shares of the firm’s stock in a transaction dated Friday, October 16th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $11,500,000.00. Following the completion of the purchase, the director directly owned 2,588,248 shares of the company’s stock, valued at $41,411,968. This trade represents a 38.45% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
About Iambic Therapeutics
Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.
Featured Articles
- Five stocks we like better than Iambic Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
